Cardiovascular Drugs and Therapy

, Volume 21, Issue 2, pp 77–79

Cerebrovascular Events After Discontinuation of Rofecoxib Treatment

Editorial

References

  1. 1.
    Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709–11.PubMedCrossRefGoogle Scholar
  2. 2.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Curfman GD, Morrissey S, Drazen JM. Expression of concern: bombardier et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med 2000;343:1520–8. N Engl J Med 2005;353:2813–4.Google Scholar
  4. 4.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092–102.PubMedCrossRefGoogle Scholar
  5. 5.
    FDA—Department of Health and Human Services. Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee. http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T1.pdf. Accessed March 1, 2007.
  6. 6.
    Merck. APPROVe Extension Statistical Package. http://www.merck.com/newsroom/vioxx/pdf/APPROVe_Extension_Statistical_Package.pdf. Accessed March 1, 2007.
  7. 7.
    McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, Fitzgerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Kudryashov SA, Tertov VV, Orekhov AN, Geling NG, Smirnov VN. Regression of atherosclerotic manifestations in primary culture of human aortic cells: effects of prostaglandins. Biomed Biochim Acta 1984;43:S284–S286.PubMedGoogle Scholar
  9. 9.
    Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 2002;296:539–41.PubMedCrossRefGoogle Scholar
  10. 10.
    Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study. Stroke 2006;37:1725–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Fitzgerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879–90.PubMedCrossRefGoogle Scholar
  12. 12.
    Serebruany VL, Malinin AI, Bhatt DL. Paradoxical rebound platelet activation after painkillers cessation: missing risk for vascular events? Am J Med 2006;119:707 e. 11–6.Google Scholar
  13. 13.
    Bogaty P, Brophy JM, Noel M, Boyer L, Simard S, Bertrand F et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 2004;110:934–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Arch Intern Med 2004;164:2472–6.PubMedCrossRefGoogle Scholar
  15. 15.
    EMEA—European Medicines Agency. Public CHMP Assessment report for medicinal products containing non-selective non steroidal anti-inflammatory drugs (NSAIDs). http://www.emea.eu.int/pdfs/human/opiniongen/44213006en.pdf. Accessed March 1, 2007.
  16. 16.
    Lagakos SW. Time-to-event analyses for long-term treatments—the APPROVe trial. N Engl J Med 2006;355:113–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen LC, Ashcroft DM. Do selective COX-2 inhibitors increase the risk of cerebrovascular events? A meta-analysis of randomized controlled trials. J Clin Pharm Ther 2006;31:565–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Charité—Universitaetsmedizin BerlinInstitute of Clinical Pharmacology and ToxicologyBerlinGermany

Personalised recommendations